ProCE Banner Activity

Individualizing Adjuvant Therapy for HR-Positive/HER2-Negative Early Breast Cancer in Your Practice

Slideset

Download this slideset on the management of patients with high-risk, early-stage HR-positive/HER2-negative breast cancer including risk assessment algorithms and the integration of adjuvant CDK4/6 inhibitors in clinical practice.

Released: April 01, 2025

Expiration: March 31, 2026

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly